M.D. Anderson Cancer Center
To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.
Primary Objectives * To demonstrate efficacy of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (nccRCC). Secondary Objectives * To assess the safety and toxicity of combination tivozanib and nivolumab. * To estimate the duration of clinical efficacy Exploratory Objectives * To associate immune and tumor biomarkers with clinical efficacy
Inclusion Criteria: 1. Patients with histologically or cytologically confirmed metastatic non-clear cell renal cell carcinoma of papillary, chromophobe, oncocytic neoplasms, unclassified, or not otherwise specified (NOS) as clear cell. Medullary carcinoma of the kidney and collecting duct tumors are NOT allowed 2. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 3. Up to 1 systemic line of therapy (either monotherapy or combination) including prior immunotherapy (anti-PD1, PD-L1, or CTLA-4) and multi-tyrosine kinase inhibitors in non-metastatic or metastatic s…
Given by PO
Given by IV (vein)
Arctuva estimate
Verify or correct the compensation shown for this listing.